Literature DB >> 8482628

Effect of delay in radiation in the combined modality treatment of breast cancer.

T A Buchholz1, M M Austin-Seymour, R E Moe, G K Ellis, R B Livingston, J G Pelton, T W Griffin.   

Abstract

PURPOSE: To study how the timing of radiation influences local control, overall survival, and disease-free survival in patients being treated with chemotherapy and radiation for a local-regional carcinoma of the breast. METHODS AND MATERIALS: Over a ten year period, 105 patients received chemotherapy and radiation treatments for a local-regional breast cancer. The population was divided into two groups based on the timing of their radiation treatments. Forty-eight patients began their radiation within 6 months of their diagnosis (early radiation group). Fifty-seven patients had a delay in their radiation for 6 or greater months in order to first maximize chemotherapy treatments (delayed radiation group). There were no significant differences between the two groups with respect to nodal status, stage of the primary, estrogen receptor status, patient age, or type of surgery performed. The only prognostic parameter that was imbalanced was that of a greater percentage of patients with close or positive margins in the early radiation group compared to the delayed radiation group (69% versus 38%, p < 0.02).
RESULTS: Comparisons of local control, overall survival, and disease-free survival between the early radiation patients and delayed radiation patients all favored the early radiation group. Respective 8-year actuarial rates were: local control--98% vs. 76%, p = 0.004; overall survival--80% vs. 52%, p = 0.016; disease-free survival--71% vs. 48%, p = 0.008. The differences continued to be significant in a multivariate Cox regression model comparison: p = 0.011, p = 0.050, p = 0.009. There was only one death from intercurrent disease, so that overall survival approximated cause-specific survival to an accurate degree.
CONCLUSIONS: In patients requiring chemotherapy and radiation treatments for a local-regional breast cancer, a delay in the initiation of radiation for a period of 6 months or greater from diagnosis resulted in a higher local failure rate. Furthermore, this higher local failure rate was associated with an increased rate of distant metastases and a decreased overall survival rate.

Entities:  

Mesh:

Year:  1993        PMID: 8482628     DOI: 10.1016/0360-3016(93)90169-v

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

1.  Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Authors:  Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

2.  Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.

Authors:  Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis
Journal:  Oncologist       Date:  2010-11-01

Review 3.  Radiation therapy after breast-conserving surgery.

Authors:  Naoyuki Shigematsu; Atsuya Takeda; Naoko Sanuki; Junichi Fukada; Takashi Uno; Hisao Ito; Osamu Kawaguchi; Etsuo Kunieda; Atsushi Kubo
Journal:  Radiat Med       Date:  2006-06

4.  Breast Cancer OncoGuia.

Authors:  Paula Manchon; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

5.  Impact of radiotherapy delay on survival in glioblastoma.

Authors:  Izaskun Valduvieco; Eugènia Verger; Jordi Bruna; Lluís Caral; Teresa Pujol; Teresa Ribalta; Teresa Boget; Laura Oleaga; Estela Pineda; Francesc Graus
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

6.  Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution.

Authors:  S Corradini; O M Niemoeller; M Niyazi; F Manapov; M Haerting; N Harbeck; C Belka; S Kahlert
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

Review 7.  The Efficacy of Prophylactic Negative Pressure Wound Therapy for Closed Incisions in Breast Surgery: A Systematic Review and Meta-Analysis.

Authors:  David Cagney; Lydia Simmons; Donal Peter O'Leary; Mark Corrigan; Louise Kelly; M J O'Sullivan; Aaron Liew; Henry Paul Redmond
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

8.  Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer.

Authors:  Francesco Recchia; Giampiero Candeloro; Alisia Cesta; Mario DI Staso; Pierluigi Bonfili; Giovanni Luca Gravina; Ernesto DI Cesare; Stefano Necozione; Silvio Rea
Journal:  Mol Clin Oncol       Date:  2014-03-21

9.  Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution.

Authors:  Nabil Ismaili; Sanaa Elmajjaoui; Issam Lalya; Lamia Boulaamane; Rhizlane Belbaraka; Halima Abahssain; Rachi Aassab; Noureddine Benjaafar; Brahim El Khalil El Guddari; Omar El Mesbahi; Yassir Sbitti; Mohammed Ismaili; Hassan Errihani
Journal:  BMC Res Notes       Date:  2010-10-04

10.  Delayed radiotherapy for breast cancer patients in integrated delivery systems.

Authors:  Heather Taffet Gold; Soe Soe Thwin; Diana S M Buist; Terry S Field; Feifei Wei; Marianne Ulcickas Yood; Timothy L Lash; Virginia P Quinn; Ann M Geiger; Rebecca A Silliman
Journal:  Am J Manag Care       Date:  2009-11       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.